Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis
Posted inCardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.
Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency
Posted inClinical Updates Diabetes & Endocrinology news Pediatrics

Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency

This meta-analysis reveals that long-acting growth hormone (LAGH) is associated with a significant increase in BMI SD scores during the first year of treatment and upon switching from daily GH, suggesting a distinct metabolic profile compared to daily regimens.
Beyond Recanalization: Understanding the Dynamic Evolution of the No-Reflow Phenomenon After Stroke Thrombectomy
Posted inNeurology news Radiology

Beyond Recanalization: Understanding the Dynamic Evolution of the No-Reflow Phenomenon After Stroke Thrombectomy

A prospective multicenter study reveals that the no-reflow phenomenon is a dynamic, evolving pathology following successful thrombectomy. It is significantly associated with infarct growth and poor functional outcomes, suggesting that achieving large vessel patency is only the first step in restoring cerebral perfusion.